EUVIMEDOpdag EUVIMED
Scoping ReviewOpen access · CC BY-NC-ND 4.0

Primary and Adjuvant Medical Management of Idiopathic Subglottic Stenosis: A Scoping Review

Hetal Lad, Sally Durant, Sai Vendidandi, Aditya Kasina, Rachel Kaye, Kenneth Yan

Laryngoscope Investigative Otolaryngology · 2026-12 · 11 (6)

DOI: 10.1002/lio2.70602 ↗

At a glance

Scoping Review in Laryngoscope Investigative Otolaryngology, published online on 2026-11-20. Written by Hetal Lad and 5 co-authors. 56 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Idiopathic subglottic stenosis (iSGS), treated primarily with endoscopic resection and dilation, has a high recurrence rate. However, the efficacy of primary and adjuvant medical therapies to prevent recurrence remains controversial.

Methods

MEDLINE, Embase, and Cochrane were searched to evaluate primary and adjuvant medical therapies in iSGS. Articles were reviewed on Covidence to identify 30 papers that were analyzed for recurrence rate, time to recurrent operation (TTR), and peak expiratory flow (PEF). Analyses were performed in R 4.4.1.

Results

The most reported medical therapy was serial intralesional steroid injections (SILSI), though therapies included everolimus, mitomycin C, rituximab, and methotrexate, lipoaspirate, and triple therapy of a proton pump inhibitor, inhaled corticosteroid, and antibiotic. Triple therapy demonstrated a TTR of 49.8 months ( n = 666). SILSI, as an adjunct to surgery, demonstrated a TTR of 23.8 months ( n = 285), while SILSI as a primary treatment ( n = 147) demonstrated a longer TTR of 28.3 months. Intraoperative steroid injection alone ( n = 125) had a TTR of 14.5 months. Mitomycin‐C ( n = 153) yielded a mean TTR of 21.8 months. Immunomodulators demonstrated mixed results as methotrexate averaged 25.5 months ( n = 13), rituximab 28.1 months ( n = 3), and methotrexate–rituximab combinations only 12.7 months to recurrent symptoms ( n = 5). Everolimus yielded a TTR of 8.5 months ( n = 7) while lipoaspirate had no recurrence for 15 months ( n = 3).

Conclusion

Adjuvant therapies, particularly triple therapy with a long TTR, suggest a potential role for medical management in iSGS. SILSI and mitomycin‐C also demonstrated meaningful recurrence delays, with SILSI alone offering TTR comparable to adjunctive use.

Cite

APA

Lad, H., Durant, S., Vendidandi, S., Kasina, A., Kaye, R., & Yan, K. (2026). Primary and Adjuvant Medical Management of Idiopathic Subglottic Stenosis: A Scoping Review. Laryngoscope Investigative Otolaryngology, 11(6). https://doi.org/10.1002/lio2.70602

Vancouver

Lad H, Durant S, Vendidandi S, Kasina A, Kaye R, Yan K. Primary and Adjuvant Medical Management of Idiopathic Subglottic Stenosis: A Scoping Review. Laryngoscope Investigative Otolaryngology. 2026;11(6). doi:10.1002/lio2.70602

BibTeX
@article{Lad2026,
  author = {Lad, Hetal and Durant, Sally and Vendidandi, Sai and Kasina, Aditya and Kaye, Rachel and Yan, Kenneth},
  title = {Primary and Adjuvant Medical Management of Idiopathic Subglottic Stenosis: A Scoping Review},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {6},
  doi = {10.1002/lio2.70602}
}
Start for free →